Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis

4Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. A number of treatment agents have undergone assessment in humans following promising results in animal models. Currently, about 50 therapeutic agents are in various stages of development. Recently, however, there have been a number of exciting and positive developments in this landscape, although there are inherent challenges ahead. In this article, we review the aetiological and pathological basis of NASH progression and describe putative targets for current therapies. We also discuss some of the likely future directions and difficulties around this complex and challenging disease paradigm.

References Powered by Scopus

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

11224Citations
N/AReaders
Get full text

Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes

8105Citations
N/AReaders
Get full text

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

2718Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)

40Citations
N/AReaders
Get full text

Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study

0Citations
N/AReaders
Get full text

Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Brennan, P. N., Dillon, J. F., & McCrimmon, R. (2022, September 22). Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis. TouchREVIEWS in Endocrinology. https://doi.org/10.17925/EE.2022.18.2.148

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Researcher 2

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

50%

Pharmacology, Toxicology and Pharmaceut... 2

33%

Biochemistry, Genetics and Molecular Bi... 1

17%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free